Results From a Time and Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease From Italian Sites.
نویسندگان
چکیده
1 Fondazione IRCCS Policlinico “San Matteo”, Pavia, Italy; 2 Fondazione IRCCS Istituto Nazionale Tumori , Milano, Italy; 3 Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy; 4 Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte, Messina, Italy; 5 A.S.L. AT, Asti, Italy; 6 CHU Brugmann, ULB, Brussels, Belgium; 7 Amgen Spa, Milan, Italy; 8 United BioSource Corporation, Barcelona, Spain; 9 United BioSource Corporation, Montreal, Canada; 10 United BioSource Corporation, London, UK; 11 Amgen (Europe) GmbH, Zug, Switzerland.
منابع مشابه
Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
PURPOSE This randomized study compared denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor κ B (RANK) ligand, with zoledronic acid in delaying or preventing skeletal-related events (SREs) in patients with breast cancer with bone metastases. PATIENTS AND METHODS Patients were randomly assigned to receive either subcutaneous denosumab 120 mg and intravenous...
متن کاملBone-related complications and quality of life in advanced breast cancer: results from a randomized phase III trial of denosumab versus zoledronic acid.
PURPOSE Denosumab was shown to be superior to zoledronic acid in preventing skeletal related events (SRE) in patients with breast cancer and bone metastases in a randomized, double-blind phase III study. We evaluated further results from this study related to skeletal complications and health-related quality of life (HRQoL). EXPERIMENTAL DESIGN Patients were randomized 1:1 to receive subcutan...
متن کاملClinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
BACKGROUND Patients with metastatic bone disease are living longer in the metastatic stage due to improvements in cancer therapy, making strategies to prevent the aggravation of bone disease and its complications, such as skeletal-related events (SREs) and pain, increasingly important. PATIENTS AND RESULTS In this phase 3 trial in patients with advanced cancer (excluding breast and prostate c...
متن کاملHypocalcaemia in patients with metastatic bone disease treated with denosumab.
BACKGROUND This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab. METHODS Laboratory abnormalities and adverse events of hypocalcaemia in patients with metastatic bone disease were analysed using data from three identically designed phase 3 trials of subcutaneous denosumab 120 mg (n = 2841) versus intravenous ...
متن کاملThe role of denosumab in the prevention of hypercalcaemia of malignancy in cancer patients with metastatic bone disease.
BACKGROUND We compared the activity of denosumab with zoledronic acid for delaying or preventing hypercalcaemia of malignancy (HCM) in patients with advanced cancer and bone metastases or with multiple myeloma. METHODS Patient-level data were combined from two identically designed, randomised, double-blind, active-controlled, phase III trials of advanced cancer patients with breast cancer and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
دوره 18 7 شماره
صفحات -
تاریخ انتشار 2015